Clinical trial
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous…
NCT00490776 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00490776 |
|---|---|
| Title | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) |
| Official title | A Phase II Study of Oral LBH589 in Adult Patients With Cutaneous T-Cell Lymphoma Who Are Intolerant to or Have Progressed on or After Prior HDAC Inhibitor |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Panobinostat |
| Enrollment | 9 |
| Start date | Jul 5, 2007 |
| Primary completion | Sep 1, 2009 |
| Completion | Sep 22, 2009 |
| First posted | Jun 25, 2007 |
| Last update posted | Aug 18, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: